Trial Profile
A two-part, open-label, cross-over study to assess the pharmacokinetics of GSK221149 [retosiban] following single oral doses of various modified release formulations and a solution in healthy adult subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2023
Price :
$35
*